

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

13th February, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)

Dear Sir(s)/Madam,

This is in furtherance to our earlier intimation dated 12th August, 2025 with regard to execution of a Shareholders’ Agreement of the said date by Alkem Laboratories Limited (“**Company**”) with Mr. Abdulaziz Alsheikh, a Saudi Arabian national (JV Partner) for incorporation of a subsidiary of the Company in the form of a Joint Venture in the Kingdom of Saudi Arabia (JV), wherein, pursuant to incorporation of the JV, the Company would hold 51% of the total share capital and the balance stake of 49% will be held by the JV Partner.

Pursuant to Regulation to 30 of the SEBI LODR Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 13th February, 2026 have approved an amendment to the Shareholders’ Agreement to be executed with the wholly owned company of the JV Partner, viz. Vitals Biotech Company, which shall now hold 49% of the share capital of the JV in place of the JV Partner himself.

The above information is also available on the website of the Company at www.alkemlabs.com.

Kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer